- Home
- TNON vs RDHL Comparison
TNON vs RDHL Comparison
Compare TNON & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNON | RDHL |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.3M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TNON | RDHL |
|---|---|---|
| Price | $3.52 | $0.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.3M | 2.5M |
| Earning Date | 05-05-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,944,000.00 | N/A |
| Revenue This Year | $65.95 | $381.91 |
| Revenue Next Year | $50.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.35 | N/A |
| 52 Week Low | $0.13 | $0.54 |
| 52 Week High | $17.84 | $2.79 |
Technical Indicators
Market Signals| Indicator | TNON | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 37.56 |
| Support Level | $0.52 | N/A |
| Resistance Level | $7.15 | $0.91 |
| Average True Range (ATR) | 1.13 | 0.05 |
| MACD | -0.22 | -0.02 |
| Stochastic Oscillator | 14.57 | 0.00 |
Price Performance
Historical ComparisonAbout TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.